Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for InnoPharmax Inc. (4172.TWO), each with what it measures. Figures are trailing twelve months or the most recent reported period.
Valuation
Metric
Value
P/E ratioShare price divided by earnings per share.
0.00
P/B ratioShare price divided by book value per share.
2.31
P/S ratioMarket value divided by annual revenue.
18.17
Profitability
Metric
Value
Gross marginRevenue left after the direct cost of goods sold.
19.60%
Operating marginRevenue left after operating costs.
-143.67%
Net marginRevenue left after every cost, including tax and interest.
0.00%
Return on equityProfit as a percentage of shareholders’ equity.
-37.62%
Return on assetsProfit as a percentage of total assets.
-20.48%
Financial health
Metric
Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.
6.42
Quick ratioThe same, excluding inventory.
5.95
Debt to equityTotal borrowings against shareholders’ equity.
0.02
Per share and size
Metric
Value
Earnings per shareProfit attributable to each share.
$-1.83
Book value per shareShareholders’ equity divided by shares outstanding.
$4.43
Shares outstandingShares currently issued.
119,575,500
Market capitalisationShare price times shares outstanding.
$1.23B
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.
$0
EmployeesReported headcount.
33
Dividend
Metric
Value
Dividend yieldAnnual dividend as a percentage of the share price.
0.00%
Payout ratioShare of profit paid out as dividends.
0.00%
InnoPharmax Inc. (4172.TWO) statistics — frequently asked questions
What is InnoPharmax Inc.'s return on equity?
InnoPharmax Inc. (4172.TWO) reports a return on equity of -37.62%, meaning it generated that much profit for every dollar of shareholders' equity.
How much debt does InnoPharmax Inc. carry?
InnoPharmax Inc. (4172.TWO) has a debt-to-equity ratio of 0.02, which compares total borrowings with shareholders' equity.